<?xml version="1.0" encoding="UTF-8"?>
<article article-type="research-article" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">global-journal-of-medical-research</journal-id>
<journal-title-group>
<journal-title>Global Journal of Medical Research</journal-title>
</journal-title-group>
<issn publication-format="print">0975-5888</issn>
<issn publication-format="electronic">2249-4618</issn>
<publisher><publisher-name>Global Journals Publishing Group Incorporated</publisher-name></publisher>
<self-uri xlink:href="https://globaljournals.org/journal-seo-export/jats/59716.xml" />
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">59716</article-id>
<title-group>
<article-title>Surrogate Parameters, Instead of the Genetic Profile, for Recurrence Risk Evaluation in â€œEarly-Stage Breast Cancer Casesâ€ in a Middle â€“ Income Country like Argentina</article-title>
<subtitle>Nomograms as Surrogates for BC Genomic Testing</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Kress</surname><given-names>Roberto P. Meiss</given-names></name><xref ref-type="aff" rid="aff1" />
</contrib>
<contrib contrib-type="author"><name><surname>Gualtieri</surname><given-names>Ariel</given-names></name></contrib>
</contrib-group>
<aff id="aff1">ARGENTINA</aff>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-04-01">
<day>01</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>22</volume>
<issue>F3</issue>
<fpage>27</fpage>
<lpage>33</lpage>
<abstract><p>Abstarct-Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide and is a leading cause of death and disability among women in low-and middleincome countries (MICs) among which is Argentina. Nowadays in BC, beyond the standard determination of cancer stage according to the classic anatomical criteria of the TNM the study of genic profile (GP) of cancer has also been encouraged. Implementation of the multigene panels assay has led to a change in the manner in which chemotherapy is utilized mainly in patients with, early stage, estrogen receptor (ER)-positive, Her2-neu negative, lymph nodenegative BC ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. Multigene panels can provide better risk discrimination relative to clinic-pathological factors. Unfortunately, all these tests are expensive.</p></abstract>
<self-uri content-type="pdf" xlink:href="https://globaljournals.org/GJMR_Volume22/4-Surrogate-Parameters-Instead-of-the-Genetic-Profile.pdf" />
<self-uri content-type="html" xlink:href="https://globaljournals.org/scholarly-articles/surrogate-parameters-instead-of-the-genetic-profile-for-recurrence-risk-evaluation-in-early-stage-breast-cancer-cases-in-a-middle-income-country-like-argentina/" />
</article-meta>
</front>
<body>
<sec>
<title>Full Text</title>
<p>Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide and is a leading cause of death and disability among women in lowand middleincome countries (MICs) among which is Argentina. Nowadays in BC, beyond the standard determination of cancer stage according to the classic anatomical criteria of the TNM the study of genic profile (GP) of cancer has also been encouraged. Implementation of the multigene panels assay has led to a change in the manner in which chemotherapy is utilized mainly in patients with, early stage, estrogen receptor (ER)-positive, Her2-neu negative, lymph nodenegative BC ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. Multigene panels can provide better risk discrimination relative to clinic-pathological factors. Unfortunately, all these tests are expensive.</p>
</sec>
</body>
</article>